Ornibel (Ethinylestradiol, Etonogestrel)

Ornibel is a combined hormonal contraceptive that acts on the reproductive endocrine system to prevent unintended pregnancy and manage menstrual disorders.

• Contraception: prevention of pregnancy in women of childbearing age.
• Menstrual cycle regulation: helps achieve regular, predictable menstrual bleeding.
• Acne treatment: reduces acne lesions in women when prescribed for this indication.

• Ethinylestradiol provides estrogenic activity while etonogestrel supplies progestogenic activity. Together they suppress the hypothalamic‑pituitary‑ovarian axis, inhibiting the mid‑cycle surge of luteinizing hormone and preventing ovulation. The progestin also thickens cervical mucus and alters the endometrial lining, creating additional barriers to fertilization and implantation.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Headache: tension‑type or migraine‑like pain.
• Breast tenderness: swelling or discomfort.
• Weight gain: modest increase in body weight.
• Mood changes: irritability or emotional lability.
• Breakthrough bleeding: spotting between periods.

Serious or Rare Side Effects

• Venous thromboembolism: deep‑vein thrombosis or pulmonary embolism.
• Arterial thrombosis: stroke or myocardial infarction.
• Hypertension: new‑onset high blood pressure.
• Liver tumor: benign hepatic adenoma.
• Gallbladder disease: cholelithiasis or cholecystitis.
• Severe allergic reaction: anaphylaxis or angioedema.

Before prescribing Ornibel, clinicians should consider the following precautions:

• Assess thromboembolic risk: evaluate personal and family history of clotting disorders.
• Avoid smoking: especially in women over 35 years of age.
• Monitor blood pressure: hypertension may develop during therapy.
• Review liver function: hepatic disease may contraindicate use.
• Check drug interactions: enzyme‑inducing agents can reduce efficacy.
• Store at ambient temperature: keep below 25°C, protect from moisture and light.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampin, phenytoin, St. John’s wort): may markedly reduce contraceptive effectiveness.
• Concurrent use with other hormonal contraceptives: risk of hormonal overdose.

Moderate Interactions (Monitor Closely)

• Antifungal agents (e.g., ketoconazole) and certain antibiotics (e.g., macrolides): may slightly lower plasma levels.
• Antihypertensive drugs: additive blood‑pressure‑lowering effect.
• Herbal supplements (e.g., ginkgo biloba): may increase bleeding tendency.